Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors

A compound and substituent technology, applied in the preparation of organic compounds, anti-inflammatory agents, drug combinations, etc., can solve the problems of insufficient efficacy of severe pain, mucosal ulcers, etc.

Active Publication Date: 2011-10-19
ARRAY BIOPHARMA
View PDF5 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nonsteroidal anti-inflammatory analgesics (NSAIDs, such as COX-1 or COX-2) also have drawbacks incl

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example A

example B

example 1

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compounds of formula (I): in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor. The formula (I) is shown in the description.

Description

technical field The present invention relates to novel compounds, pharmaceutical compositions comprising these compounds, processes for the preparation of these compounds and the use of these compounds in therapy. More specifically, the present invention relates to certain substituted imidazo[1,2-b]pyridazine compounds that exhibit Trk family protein tyrosine kinase inhibition and are useful in the treatment of pain, inflammation, cancer and certain infections disease. Background technique Current treatment regimens for painful conditions utilize several classes of compounds. Opioids such as morphine have several drawbacks including causing vomiting, constipation and negative respiratory effects, as well as possible addiction. Non-steroidal anti-inflammatory analgesics (NSAIDs, eg of type COX-1 or COX-2) also have drawbacks including insufficient potency in treating severe pain. In addition, COX-1 inhibitors can cause mucosal ulceration. Accordingly, there is a continuin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D471/04A61K31/5025A61P29/00
CPCC07D487/04A61K31/5025A61K31/5377A61K31/541A61P1/02A61P11/06A61P15/12A61P17/04A61P17/06A61P19/00A61P19/02A61P19/08A61P19/10A61P25/00A61P25/04A61P25/28A61P29/00A61P33/00A61P33/02A61P33/10A61P35/00A61P35/04A61P43/00C07D471/04C07D519/00Y02A50/30C07C51/412C07C53/18
Inventor 史蒂文.W.安德鲁斯朱莉娅.哈斯蒋于桐张敢
Owner ARRAY BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap